Get the Stockscreener App
243.09
0.66%
-1.61
After Hours:
246.90
3.81
+1.57%
Overview
News
Price History
Option Chain
Financials
Why RMD Down?
Discussions
Forecast
Stock Split
Dividend History
Resmed Inc stock is traded at $243.09, with a volume of 737.77K.
It is down -0.66% in the last 24 hours and up +18.85% over the past month.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
See More
Previous Close:
$244.70
Open:
$245.74
24h Volume:
737.77K
Relative Volume:
0.72
Market Cap:
$35.70B
Revenue:
$5.02B
Net Income/Loss:
$1.31B
P/E Ratio:
27.28
EPS:
8.91
Net Cash Flow:
$1.56B
1W Performance:
+2.79%
1M Performance:
+18.85%
6M Performance:
-3.68%
1Y Performance:
+14.19%
1-Day Range:
$242.77
$247.35
1-Week Range:
$237.00
$247.35
52-Week Range:
$179.42
$263.05
Resmed Inc Stock (RMD) Company Profile
Name
Resmed Inc
Sector
Industry
Phone
(858) 746-2400
Address
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
243.09 | 35.70B | 5.02B | 1.31B | 1.56B | 8.91 |
|
ISRG
Intuitive Surgical Inc
|
538.16 | 185.37B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
167.95 | 48.59B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
95.88 | 47.57B | 9.91B | 1.02B | 665.00M | 2.05 |
|
COO
The Cooper Companies, Inc.
|
82.92 | 16.51B | 3.90B | 392.30M | 288.10M | 1.95 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-19-25 | Initiated | Morgan Stanley | Overweight |
| Jan-16-25 | Initiated | Goldman | Buy |
| Jan-10-25 | Initiated | Piper Sandler | Neutral |
| Dec-13-24 | Initiated | Stifel | Hold |
| Sep-24-24 | Initiated | Robert W. Baird | Outperform |
| Sep-18-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-04-24 | Downgrade | Needham | Buy → Hold |
| Jun-25-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-24-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Oct-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-12-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-09-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-29-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-06-23 | Upgrade | Needham | Hold → Buy |
| Sep-05-23 | Downgrade | UBS | Buy → Neutral |
| Aug-01-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-23-23 | Initiated | UBS | Buy |
| Apr-14-23 | Initiated | Mizuho | Buy |
| Jan-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-28-22 | Downgrade | Citigroup | Buy → Neutral |
| Oct-20-22 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Sep-08-22 | Upgrade | Citigroup | Neutral → Buy |
| Aug-15-22 | Downgrade | CLSA | Buy → Outperform |
| Aug-12-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-12-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-06-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-31-22 | Upgrade | Citigroup | Neutral → Buy |
| Jan-31-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-28-22 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Jan-24-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-24-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-13-22 | Upgrade | CLSA | Outperform → Buy |
| Jan-13-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-21-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Dec-06-21 | Upgrade | Macquarie | Neutral → Outperform |
| Oct-22-21 | Upgrade | CLSA | Underperform → Outperform |
| Aug-02-21 | Downgrade | CLSA | Outperform → Sell |
| Aug-02-21 | Downgrade | Needham | Buy → Hold |
| Jul-28-21 | Upgrade | Jefferies | Underperform → Hold |
| Jul-26-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-14-21 | Initiated | RBC Capital Mkts | Underperform |
| Jun-28-21 | Downgrade | Citigroup | Buy → Neutral |
| Jun-22-21 | Upgrade | Macquarie | Neutral → Outperform |
| Jun-22-21 | Initiated | Robert W. Baird | Neutral |
| Jun-21-21 | Reiterated | Needham | Buy |
| Jun-16-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-09-21 | Upgrade | CLSA | Sell → Outperform |
| May-21-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-30-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-21 | Upgrade | Needham | Hold → Buy |
| Nov-02-20 | Upgrade | UBS | Neutral → Buy |
| Oct-30-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-27-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-07-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-17-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-01-20 | Downgrade | JP Morgan | Neutral → Underweight |
| May-01-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-03-20 | Initiated | CLSA | Underperform |
| Jan-31-20 | Downgrade | UBS | Buy → Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Perform |
| Nov-22-19 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jul-29-19 | Upgrade | UBS | Neutral → Buy |
| Jul-16-19 | Downgrade | UBS | Buy → Neutral |
| May-06-19 | Upgrade | UBS | Neutral → Buy |
| Apr-18-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-25-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-25-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-26-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jul-02-18 | Initiated | Goldman | Buy |
View All
Resmed Inc Stock (RMD) Latest News
Insider Sell: Peter Farrell Sells 2,000 Shares of ResMed Inc (RMD) - GuruFocus
Resmed prevails over Cleveland Medical in CPAP patent review - BioWorld MedTech
Is ResMed Inc.'s (NYSE:RMD) Latest Stock Performance A Reflection Of Its Financial Health? - simplywall.st
Ex-Dividend Reminder: Seaboard, KB Home and ResMed - Nasdaq
ResMed Inc Reports Changes in CDIs and Securities for April 2025 - TipRanks
Jim Cramer on Viemed Healthcare (VMD): “Interesting, But I’m a ResMed Guy” - Yahoo Finance
ResMed Wins Invalidation of Sleep Apnea Tech Patent After Remand - Bloomberg Law News
Is It Smart To Buy ResMed Inc. (NYSE:RMD) Before It Goes Ex-Dividend? - Yahoo Finance
ResMed Corporation: GLP-1 Demand Generation Strategy to Expand Customer Base & Strengthen Their Position! - Smartkarma
Intuitive wins new FDA nod for single port robot; Resmed buys diagnostic facility - MedTech Dive
This ResMed Insider Reduced Their Stake By 72% - Yahoo Finance
Resmed acquires independent diagnostic testing facility VirtuOx - Yahoo Finance
Resmed Acquires Virtual Care Company VirtuOx - Medical Product Outsourcing
ResMed (RMD) Expands with VirtuOx Acquisition - GuruFocus
Resmed Acquires VirtuOx - Nasdaq
ResMed Buys VirtuOx for Undisclosed sum - marketscreener.com
Resmed (RMD) Expands Reach with Acquisition of VirtuOx | RMD Sto - GuruFocus
Resmed acquires virtual diagnostics company VirtuOx - MassDevice
Resmed (RMD) Expands Reach with Acquisition of VirtuOx | RMD Stock News - GuruFocus
Why ResMed (RMD) is a Top Growth Stock for the Long-Term - Yahoo Finance
ResMed announces it has acquired VirtuOx - TipRanks
Resmed Inc (RMD): Jim Cramer Says “Remarkable Stock” — Did GLP-1 Drugs Just Hand It a Lifeline? - Insider Monkey
This ASX medical device company has a Trump tariff exemption - MSN
Resmed Hires Chief Investor Relations Officer - HME Business
Press Release Distribution & PR Platform - ACCESS Newswire
ResMed Inc. Files Quarterly Report, Reinforces Market Position - MSN
ASX healthcare leader continues to prove the doubters wrong - Morningstar
What does Macquarie think ResMed shares are worth? - MSN
ResMed brushes off tariff threat - Intelligent Investor
ResMed Q3 Earnings and Revenues Beat, Stock Up in After-Market - MSN
ResMed Q1 2025: Strong Sales Growth and Strategic InitiativesNews and Statistics - IndexBox
ResMed Inc. (NYSE:RMD) Q3 2025 Earnings Call Transcript - Insider Monkey
ResMed Inc’s Earnings Call Highlights Growth and Innovation - TipRanks
ResMed Inc (RMD)'s Winning Formula: Financial Metrics and Compet - GuruFocus
ResMed (RMD) is a Top-Ranked Momentum Stock: Should You Buy? - Yahoo Finance
Decoding ResMed Inc (RMD): A Strategic SWOT Insight - GuruFocus
ResMed Inc. stock rises Thursday, outperforms market - MSN
ResMed Boasts Double-Digit EPS Growth, Tariff Exemption: Analysts Boost Price ForecastResMed (NYSE:RMD) - Benzinga
ResMed (NYSE:RMD) Reports Strong Q3 Earnings Growth and Declares US$0.53 Dividend - Yahoo Finance
ResMed (RMD) Q3 Earnings and Revenues Surpass Estimates - MSN
ResMed Inc (RMD) Shares Up 11.28% on Apr 24 - GuruFocus
ResMed price target raised to $255 from $247 at RBC Capital - TipRanks
Jefferies Adjusts Price Target on ResMed to $245 From $270, Maintains Hold Rating - marketscreener.com
Morgan Stanley Adjusts Price Target on ResMed to $286 From $280, Maintains Overweight Rating - marketscreener.com
ResMed stock holds as Oppenheimer maintains Perform rating By Investing.com - Investing.com Canada
Texas Instruments Posts Better-Than-Expected Results, Joins Community Health Systems, Hasbro, ServiceNow, ResMed And Other Big Stocks Moving Higher On ThursdayArdagh Metal Packaging (NYSE:AMBP), Allegion (NYSE:ALLE) - Benzinga
Stifel maintains ResMed stock hold rating and $240 target - Investing.com
Stifel maintains ResMed stock hold rating and $240 target By Investing.com - Investing.com UK
ResMed stock price target raised to $255 at RBC Capital - Investing.com
Piper Sandler cuts ResMed stock price target to $248 - Investing.com
Piper Sandler cuts ResMed stock price target to $248 By Investing.com - Investing.com UK
Resmed Inc Stock (RMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.23%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):